Published in Biomaterials on November 10, 2011
Nanotheranostics--a review of recent publications. Int J Nanomedicine (2012) 1.02
In vitro interaction of colloidal nanoparticles with mammalian cells: What have we learned thus far? Beilstein J Nanotechnol (2014) 0.90
Folate-conjugated gold nanoparticle as a new nanoplatform for targeted cancer therapy. J Cancer Res Clin Oncol (2016) 0.86
Synthesis and characterization of glycol chitosan DNA nanoparticles for retinal gene delivery. ChemMedChem (2013) 0.80
Yttrium oxide nanoparticles prevent photoreceptor death in a light-damage model of retinal degeneration. Free Radic Biol Med (2014) 0.78
Non-Cytotoxic Quantum Dot-Chitosan Nanogel Biosensing Probe for Potential Cancer Targeting Agent. Nanomaterials (Basel) (2015) 0.75
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem (1969) 15.62
Development and validation of a genetic algorithm for flexible docking. J Mol Biol (1997) 14.36
Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer (2005) 13.49
Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater (2005) 12.97
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A (2007) 4.77
Self-assembled nanoscale biosensors based on quantum dot FRET donors. Nat Mater (2003) 4.19
Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano (2008) 3.88
Multifunctional magnetic nanoparticles: design, synthesis, and biomedical applications. Acc Chem Res (2009) 3.04
A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res (2003) 2.55
Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett (2007) 2.40
The role of glutathione and glutathione transferases in chemical carcinogenesis. Crit Rev Biochem Mol Biol (1990) 2.11
Designing multifunctional quantum dots for bioimaging, detection, and drug delivery. Chem Soc Rev (2010) 2.08
All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew Chem Int Ed Engl (2009) 1.77
Proteolytic activity monitored by fluorescence resonance energy transfer through quantum-dot-peptide conjugates. Nat Mater (2006) 1.66
In vivo magnetomotive optical molecular imaging using targeted magnetic nanoprobes. Proc Natl Acad Sci U S A (2010) 1.65
A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol (2010) 1.56
Nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging. Acc Chem Res (2009) 1.42
Molecular imaging of tumor angiogenesis using alphavbeta3-integrin targeted multimodal quantum dots. Angiogenesis (2008) 1.37
Fluorescent nanoparticle uptake for brain tumor visualization. Neoplasia (2006) 1.33
Synthesis of water-dispersible fluorescent, radio-opaque, and paramagnetic CdS:Mn/ZnS quantum dots: a multifunctional probe for bioimaging. J Am Chem Soc (2005) 1.31
Magnetic and fluorescent nanoparticles for multimodality imaging. Nanomedicine (Lond) (2007) 1.28
Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. Chembiochem (2009) 1.20
Combined magnetic resonance and fluorescence imaging of the living mouse brain reveals glioma response to chemotherapy. Neuroimage (2008) 1.16
Quantum-dot/dopamine bioconjugates function as redox coupled assemblies for in vitro and intracellular pH sensing. Nat Mater (2010) 1.15
Iron oxide nanoparticle-containing microbubble composites as contrast agents for MR and ultrasound dual-modality imaging. Biomaterials (2011) 1.12
Optical imaging and magnetic field targeting of magnetic nanoparticles in tumors. ACS Nano (2010) 1.02
Biofunctionalized, phosphonate-grafted, ultrasmall iron oxide nanoparticles for combined targeted cancer therapy and multimodal imaging. Small (2009) 0.99
Biocompatible magnetofluorescent probes: luminescent silicon quantum dots coupled with superparamagnetic iron(III) oxide. ACS Nano (2010) 0.98
Synthesis of Complexable Fluorescent Superparamagnetic Iron Oxide Nanoparticles (FL SPIONs) and Cell Labeling for Clinical Application. Adv Mater (2008) 0.90
Multimodal tumor imaging by iron oxides and quantum dots formulated in poly (lactic acid)-D-alpha-tocopheryl polyethylene glycol 1000 succinate nanoparticles. Biomaterials (2011) 0.89
Quantum dots for multimodal molecular imaging of angiogenesis. Angiogenesis (2010) 0.84
A simple strategy for quantum dot assisted selective detection of cadmium ions. Chem Commun (Camb) (2008) 0.78
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Cardiovascular disease in kidney donors: matched cohort study. BMJ (2012) 5.00
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A (2007) 4.77
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene (2005) 3.05
Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res (2006) 3.00
Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol (2005) 2.96
Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs (2009) 2.58
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene (2003) 2.54
STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res (2008) 2.46
IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J Am Soc Nephrol (2009) 2.43
Stat3 controls lysosomal-mediated cell death in vivo. Nat Cell Biol (2011) 2.28
Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A (2005) 2.00
Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A (2012) 1.94
Nanoparticles for bioimaging. Adv Colloid Interface Sci (2006) 1.83
An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol (2007) 1.79
Marked variation in the definition and diagnosis of delayed graft function: a systematic review. Nephrol Dial Transplant (2008) 1.74
Methylation-mediated repression of microRNA 129-2 enhances oncogenic SOX4 expression in HCC. Liver Int (2013) 1.71
A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY) (2010) 1.70
Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther (2006) 1.69
Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res (2010) 1.60
A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol (2010) 1.56
Cytoplasmic transport of Stat3 by receptor-mediated endocytosis. EMBO J (2002) 1.43
The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies? Cancer Res (2008) 1.43
Signal transducer and activator of transcription 3 inhibitors: a patent review. Expert Opin Ther Pat (2010) 1.40
Single-molecule spectroscopy of conjugated polymers. Acc Chem Res (2005) 1.40
Hepatitis C virus (HCV) constitutively activates STAT-3 via oxidative stress: role of STAT-3 in HCV replication. J Virol (2005) 1.39
Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem (2008) 1.38
Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension (2008) 1.37
Transcriptional pathways associated with skeletal muscle disuse atrophy in humans. Physiol Genomics (2007) 1.35
Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov (2013) 1.33
A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells. PLoS One (2011) 1.29
Age-related differences in lower-limb muscle cross-sectional area and torque production in boys with Duchenne muscular dystrophy. Arch Phys Med Rehabil (2010) 1.24
Skeletal muscles of ambulant children with Duchenne muscular dystrophy: validation of multicenter study of evaluation with MR imaging and MR spectroscopy. Radiology (2013) 1.22
Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders. Chembiochem (2008) 1.21
Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. Chembiochem (2009) 1.20
Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells. Oncogene (2004) 1.19
Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains. Bioorg Med Chem Lett (2007) 1.15
Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report. Anticancer Drugs (2011) 1.14
Apoptosis, senescence, and autophagy in rat nucleus pulposus cells: Implications for diabetic intervertebral disc degeneration. J Orthop Res (2012) 1.14
Long-term skeletal muscle protection after gene transfer in a mouse model of LGMD-2D. Mol Ther (2007) 1.13
Changes in muscle T2 and tissue damage after downhill running in mdx mice. Muscle Nerve (2011) 1.13
Relative contributions of muscle activation and muscle size to plantarflexor torque during rehabilitation after immobilization. J Orthop Res (2006) 1.13
The R(h)oads to Stat3: Stat3 activation by the Rho GTPases. Exp Cell Res (2011) 1.12
The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition. BMC Cancer (2012) 1.12
Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src. J Pharmacol Exp Ther (2010) 1.12
Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther (2002) 1.11
Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine (2012) 1.11
Changes in inorganic phosphate and force production in human skeletal muscle after cast immobilization. J Appl Physiol (1985) (2004) 1.10
A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro. J Biol Chem (2010) 1.09
Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem Cell Biol (2009) 1.09
Lower-extremity muscle cross-sectional area after incomplete spinal cord injury. Arch Phys Med Rehabil (2006) 1.06
Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping. Mol Ther (2011) 1.05
Chemical shift-based MRI to measure fat fractions in dystrophic skeletal muscle. Magn Reson Med (2013) 1.05
Progress towards the development of SH2 domain inhibitors. Chem Soc Rev (2013) 1.05
Wnt5a as a predictor in poor clinical outcome of patients and a mediator in chemoresistance of ovarian cancer. Int J Gynecol Cancer (2011) 1.05
The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak. Mol Cancer (2013) 1.04
Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity. J Med Chem (2012) 1.03
Fluorescent nanoparticle probes for cancer imaging. Technol Cancer Res Treat (2005) 1.02
Sensitization of pancreatic cancer cells to radiation by cerium oxide nanoparticle-induced ROS production. Nanomedicine (2012) 1.01
Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Bioorg Med Chem Lett (2011) 1.00
Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 10074-G5. Oncotarget (2013) 1.00
Stat3 is required for full neoplastic transformation by the Simian Virus 40 large tumor antigen. Mol Biol Cell (2005) 0.99
Metabolic costs of isometric force generation and maintenance of human skeletal muscle. Am J Physiol Endocrinol Metab (2002) 0.99
Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules. ChemMedChem (2011) 0.99
Noninvasive monitoring and tracking of muscle stem cell transplants. Transplantation (2004) 0.99
Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro. Oncol Rep (2009) 0.98
Endovascular surgery for proximal posterior inferior cerebellar artery aneurysms: an analysis of Glasgow Outcome Score by Hunt-Hess grades. Neurosurgery (2006) 0.98
Relaxation of the rigid backbone of an oligoamide-foldamer-based α-helix mimetic: identification of potent Bcl-xL inhibitors. Org Biomol Chem (2012) 0.98
Pharmacophore identification of c-Myc inhibitor 10074-G5. Bioorg Med Chem Lett (2012) 0.98
Silica-based multimodal/multifunctional nanoparticles for bioimaging and biosensing applications. Nanomedicine (Lond) (2008) 0.97
Noninvasive monitoring of muscle damage during reloading following limb disuse. Muscle Nerve (2005) 0.97
Biosensor-based small molecule fragment screening with biolayer interferometry. J Comput Aided Mol Des (2011) 0.96
Altering pyridinone N-substituents to optimise activity as potential prodrugs for Alzheimer's disease. Dalton Trans (2008) 0.95
Gold-Speckled Multimodal Nanoparticles for Noninvasive Bioimaging. Chem Mater (2008) 0.95
Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. J Med Chem (2006) 0.95
The RhoU/Wrch1 Rho GTPase gene is a common transcriptional target of both the gp130/STAT3 and Wnt-1 pathways. Biochem J (2009) 0.94
Protein recognition and denaturation by self-assembling fragments on a DNA quadruplex scaffold. Angew Chem Int Ed Engl (2007) 0.94
Syntheses and applications of Mn-doped II-VI semiconductor nanocrystals. J Nanosci Nanotechnol (2005) 0.94
Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression. Exp Cell Res (2007) 0.93